Obidoxime: Difference between revisions
m (Protected "Obidoxime": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
No edit summary |
||
Line 1: | Line 1: | ||
{{ | {{Refimprove|date=July 2009}} | ||
| IUPAC_name | {{Drugbox | ||
| image | | Verifiedfields = changed | ||
| verifiedrevid = 462263966 | |||
| | | IUPAC_name = 1,1'-[oxybis(methylene)]bis{4-[(''E'')-<br>(hydroxyimino)methyl]pyridinium} | ||
| image = Obidoxime.png | |||
<!--Clinical data--> | |||
| tradename = | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| pregnancy_US = <!-- A / B / C / D / X --> | |||
| pregnancy_category = | |||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | |||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | |||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | |||
| pregnancy_AU | | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | ||
| pregnancy_US | | legal_status = | ||
| pregnancy_category= | | routes_of_administration = | ||
| legal_AU | |||
| legal_CA | <!--Pharmacokinetic data--> | ||
| legal_UK | | bioavailability = | ||
| legal_US | | protein_bound = | ||
| legal_status | | metabolism = | ||
| routes_of_administration = | | elimination_half-life = | ||
| excretion = [[Kidney|Renal]] | |||
<!--Identifiers--> | |||
| CAS_number_Ref = {{cascite|changed|??}} | |||
| CAS_number = 114-90-9 | |||
| ATC_prefix = V03 | |||
| ATC_suffix = AB13 | |||
| PubChem = 5485192 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 4588647 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = N6KNE1QA9O | |||
| ChEMBL_Ref = {{ebicite|changed|EBI}} | |||
| ChEMBL = 291233 | |||
<!--Chemical data--> | |||
| C=14 | H=16 | N=4 | O=3 | charge = +2 | |||
| molecular_weight = 288.302 g/mol | |||
| smiles = O=[NH+]\C=C1\C=C/N(/C=C1)COCN/2/C=C\C(C=C\2)=C\[NH+]=O | |||
| InChI = 1/C14H14N4O3/c19-15-9-13-1-5-17(6-2-13)11-21-12-18-7-3-14(4-8-18)10-16-20/h1-10H,11-12H2/p+2 | |||
| InChIKey = HIGRLDNHDGYWQJ-SKRXCDHZAW | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C14H14N4O3/c19-15-9-13-1-5-17(6-2-13)11-21-12-18-7-3-14(4-8-18)10-16-20/h1-10H,11-12H2/p+2 | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = HIGRLDNHDGYWQJ-UHFFFAOYSA-P | |||
}} | }} | ||
'''Obidoxime''' is a member of the [[oxime]] family used to treat [[nerve gas]] poisoning. Oximes are drugs known for their ability to reverse the binding of [[organophosphorus]] compounds to the enzyme [[acetylcholinesterase]] (AChE). | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Obidoxime''' is a member of the [[oxime]] family used to treat [[nerve gas]] poisoning. Oximes are drugs known for their ability to reverse the binding of [[organophosphorus]] compounds to the enzyme [[acetylcholinesterase]] (AChE).<ref name="pmid19519385">{{cite journal |author=Jokanović M, Prostran M |title=Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds |journal=Curr. Med. Chem. |volume=16 |issue=17 |pages=2177–88 |year=2009 |pmid=19519385 |doi= 10.2174/092986709788612729|url=http://www.bentham-direct.org/pages/content.php?CMC/2009/00000016/00000017/0004C.SGM}}</ref> | |||
AChE is an enzyme that removes [[acetylcholine]] from the [[synapse]] after it creates the required stimulation on the next [[nerve cell]]. If it gets inhibited, acetylcholine is not removed after the stimulation and multiple stimulations are made, resulting in muscle contractions and [[paralysis]]. | AChE is an enzyme that removes [[acetylcholine]] from the [[synapse]] after it creates the required stimulation on the next [[nerve cell]]. If it gets inhibited, acetylcholine is not removed after the stimulation and multiple stimulations are made, resulting in muscle contractions and [[paralysis]]. | ||
[[Organophosphate]]s (such as nerve gases) are well known inhibitors of AChE. They bind to a specific place on the enzyme and prevent it from functioning normally by changing the [[Hydroxyl|OH group]] on the [[serine]] residue and by [[proton]]ating (quaternary [[nitrogen]], R<sub>4</sub>N<sup>+</sup>) the nearby nitrogen atom located in the [[histidine]] residue. | [[Organophosphate]]s (such as nerve gases) are well-known inhibitors of AChE. They bind to a specific place on the enzyme and prevent it from functioning normally by changing the [[Hydroxyl|OH group]] on the [[serine]] residue and by [[proton]]ating (quaternary [[nitrogen]], R<sub>4</sub>N<sup>+</sup>) the nearby nitrogen atom located in the [[histidine]] residue. | ||
==Function== | ==Function== | ||
Oximes such as obidoxime, [[pralidoxime]] and [[asoxime]] (HI-6) are used to restore enzyme functionality. They have greater affinity for the organic phosphate residue than the enzyme and they remove the phosphate group, restore the OH to serine and turn nitrogen from histidine back into its R<sub>3</sub>N form (tertiary nitrogen). This results in full enzyme recovery and the phosphate-oxime compound is eliminated from the organism via [[urine]]. | Oximes such as obidoxime, [[pralidoxime]] and [[asoxime]] (HI-6) are used to restore enzyme functionality. They have greater affinity for the organic phosphate residue than the enzyme and they remove the phosphate group, restore the OH to serine and turn nitrogen from histidine back into its R<sub>3</sub>N form (tertiary nitrogen). This results in full enzyme recovery and the phosphate-oxime compound is eliminated from the organism via [[urine]]. | ||
==Side effects== | ==Side effects== | ||
Oximes like these do have side effects and they include [[liver]] damage, [[kidney]] damage, [[nausea]], [[vomiting]], but they are very efficient [[antidote]]s to nerve gas poisoning. Usually treatment of poisoning includes the use of [[atropine]], which can slow down the action of the poison, giving more time to apply the oxime. | |||
==References== | |||
{{Reflist|2}} | |||
{{Antidotes}} | {{Antidotes}} | ||
[[Category:Antidotes]] | [[Category:Antidotes]] | ||
[[Category:Oximes]] | |||
[[Category:Quaternary ammonium compounds]] | |||
[[Category:Ethers]] | |||
[[Category:Drug]] |
Revision as of 18:44, 9 April 2015
This article needs additional citations for verification. (July 2009) (Learn how and when to remove this template message) |
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C14H16N4O3+2 |
Molar mass | 288.302 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Obidoxime |
Articles |
---|
Most recent articles on Obidoxime |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Obidoxime at Clinical Trials.gov Clinical Trials on Obidoxime at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Obidoxime
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Obidoxime Discussion groups on Obidoxime Directions to Hospitals Treating Obidoxime Risk calculators and risk factors for Obidoxime
|
Healthcare Provider Resources |
Causes & Risk Factors for Obidoxime |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Obidoxime is a member of the oxime family used to treat nerve gas poisoning. Oximes are drugs known for their ability to reverse the binding of organophosphorus compounds to the enzyme acetylcholinesterase (AChE).[1]
AChE is an enzyme that removes acetylcholine from the synapse after it creates the required stimulation on the next nerve cell. If it gets inhibited, acetylcholine is not removed after the stimulation and multiple stimulations are made, resulting in muscle contractions and paralysis.
Organophosphates (such as nerve gases) are well-known inhibitors of AChE. They bind to a specific place on the enzyme and prevent it from functioning normally by changing the OH group on the serine residue and by protonating (quaternary nitrogen, R4N+) the nearby nitrogen atom located in the histidine residue.
Function
Oximes such as obidoxime, pralidoxime and asoxime (HI-6) are used to restore enzyme functionality. They have greater affinity for the organic phosphate residue than the enzyme and they remove the phosphate group, restore the OH to serine and turn nitrogen from histidine back into its R3N form (tertiary nitrogen). This results in full enzyme recovery and the phosphate-oxime compound is eliminated from the organism via urine.
Side effects
Oximes like these do have side effects and they include liver damage, kidney damage, nausea, vomiting, but they are very efficient antidotes to nerve gas poisoning. Usually treatment of poisoning includes the use of atropine, which can slow down the action of the poison, giving more time to apply the oxime.
References
- ↑ Jokanović M, Prostran M (2009). "Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds". Curr. Med. Chem. 16 (17): 2177–88. doi:10.2174/092986709788612729. PMID 19519385.
- Pages with script errors
- Articles needing additional references from July 2009
- Articles with invalid date parameter in template
- All articles needing additional references
- Articles with changed CASNo identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Antidotes
- Oximes
- Quaternary ammonium compounds
- Ethers
- Drug